Skip to main content
. 2012 May 21;120(7):1390–1397. doi: 10.1182/blood-2012-03-378919

Figure 1.

Figure 1

Graphic representation of the estimated outcome with 2 different strategies for frontline CML therapy. (A) Standard-dose imatinib first, followed by salvage therapy with second-generation TKI on failure. (B) Second-generation TKI first.